{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:47:14Z","timestamp":1791935234060,"version":"4.3.4"},"reference-count":61,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100006407","name":"Natural Science Foundation of Henan Province","doi-asserted-by":"publisher","award":["262300421589"],"award-info":[{"award-number":["262300421589"]}],"id":[{"id":"10.13039\/501100006407","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100017700","name":"Henan Provincial Science and Technology Research Project","doi-asserted-by":"publisher","award":["262102310553"],"award-info":[{"award-number":["262102310553"]}],"id":[{"id":"10.13039\/501100017700","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118534","type":"journal-article","created":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T15:06:35Z","timestamp":1791644795000},"page":"118534","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P3","title":["A GLP-1\/apelin dual receptor agonist shows neuroprotective effects in the MPTP mouse model of Parkinson\u2019s disease"],"prefix":"10.1016","volume":"254","author":[{"given":"Ao","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinuo","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-7096-6499","authenticated-orcid":false,"given":"Enhua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ange","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feiyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Flatt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victor","family":"Gault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4855-964X","authenticated-orcid":false,"given":"Nigel","family":"Irwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"H\u00f6lscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijuan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2026.118534_b0005","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/mds.26122","article-title":"Levodopa: 50 years of a revolutionary drug for Parkinson disease","volume":"30","author":"Fahn","year":"2015","journal-title":"Movement Disorders : Official Journal of the Movement Disorder Society"},{"key":"10.1016\/j.bcp.2026.118534_b0010","doi-asserted-by":"crossref","first-page":"17013","DOI":"10.1038\/nrdp.2017.13","volume":"3","author":"Poewe","year":"2017","journal-title":"Parkinson Disease. Nat Rev Dis Primers"},{"key":"10.1016\/j.bcp.2026.118534_b0015","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1042\/BST20140016","article-title":"Insulin, incretins and other growth factors as potential novel treatments for Alzheimer's and Parkinson's diseases","volume":"42","author":"Holscher","year":"2014","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.bcp.2026.118534_b0020","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1080\/14728222.2022.2079492","article-title":"Therapeutic application of GLP-1 and GIP receptor agonists in Parkinson's disease","volume":"26","author":"Yang","year":"2022","journal-title":"Expert Opin. Ther. Targets"},{"key":"10.1016\/j.bcp.2026.118534_b0025","doi-asserted-by":"crossref","first-page":"337","DOI":"10.3233\/JPD-140364","article-title":"Motor and Cognitive Advantages Persist 12 months after Exenatide Exposure in Parkinson's Disease","volume":"4","author":"Aviles-Olmos","year":"2014","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.bcp.2026.118534_b0030","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1016\/S0140-6736(17)31585-4","article-title":"Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"390","author":"Athauda","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118534_b0035","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1001\/jamaneurol.2018.4304","article-title":"Utility of Neuronal-Derived Exosomes to Examine Molecular Mechanisms that Affect Motor Function in patients with Parkinson Disease: a Secondary Analysis of the Exenatide-PD Trial","volume":"76","author":"Athauda","year":"2019","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.bcp.2026.118534_b0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2024.109952","article-title":"Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: a revolution in the making?","volume":"253","author":"Holscher","year":"2024","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2026.118534_b0045","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1056\/NEJMoa2312323","article-title":"Trial of Lixisenatide in Early Parkinson\u2019s Disease","volume":"390","author":"Meissner","year":"2024","journal-title":"N. Engl. J. Med."},{"issue":"15","key":"10.1016\/j.bcp.2026.118534_b0050","article-title":"Potential Therapeutic Role for Apelin and Related Peptides in Diabetes: an Update","volume":"11","author":"Palmer","year":"2022","journal-title":"Clin Med Insights Endocrinol Diabetes."},{"issue":"1","key":"10.1016\/j.bcp.2026.118534_b0055","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1186\/s12864-018-4613-1","article-title":"A high-resolution genetic linkage map and QTL fine mapping for growth-related traits and sex in the Yangtze River common carp (Cyprinus carpio haematopterus)","volume":"19","author":"Feng","year":"2018","journal-title":"BMC Genomics"},{"issue":"2","key":"10.1016\/j.bcp.2026.118534_b0060","doi-asserted-by":"crossref","first-page":"237","DOI":"10.35946\/arcr.v37.2.08","article-title":"The Role of Innate Immunity in Alcoholic Liver Disease","volume":"37","author":"Nagy","year":"2015","journal-title":"Alcohol Res."},{"key":"10.1016\/j.bcp.2026.118534_b0065","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cca.2018.05.012","article-title":"Review: Apelin in disease","volume":"483","author":"Antushevich","year":"2018","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.bcp.2026.118534_b0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146334","article-title":"Apelin-36 mitigates MPTP\/MPP(+)-induced neurotoxicity: Involvement of alpha-synuclein and endoplasmic reticulum stress","volume":"1721","author":"Zhu","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2026.118534_b0075","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.70120","article-title":"The future of G protein-coupled receptor therapeutics: Apelin receptor acts as a prototype for the advancement of precision drug design","volume":"14","author":"Wang","year":"2024","journal-title":"Clin. Transl. Med."},{"key":"10.1016\/j.bcp.2026.118534_b0080","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.brainres.2019.03.027","article-title":"Apelin-13 protects dopaminergic neurons in MPTP-induced Parkinson's disease model mice through inhibiting endoplasmic reticulum stress and promoting autophagy","volume":"1715","author":"Zhu","year":"2019","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2026.118534_b0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.brainres.2019.146493","article-title":"Apelin-36 mediates neuroprotective effects by regulating oxidative stress, autophagy and apoptosis in MPTP-induced Parkinson's disease model mice","volume":"1726","author":"Zhu","year":"2020","journal-title":"Brain Res."},{"key":"10.1016\/j.bcp.2026.118534_b0090","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21218376","article-title":"Apelin-13 Protects Dopaminergic Neurons against Rotenone-Induced Neurotoxicity through the AMPK\/mTOR\/ULK-1 Mediated Autophagy Activation","volume":"21","author":"Chen","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118534_b0095","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.neuroscience.2015.06.054","article-title":"Neuroprotective effects of lixisenatide and liraglutide in the MPTP mouse model of Parkinson\u2019s disease","volume":"303","author":"Liu","year":"2015","journal-title":"Neuroscience"},{"key":"10.1016\/j.bcp.2026.118534_b0100","doi-asserted-by":"crossref","unstructured":"Feng, P., Zhang, X., Li, D., C., J., Yuan, Z., Wang, R., Xue, G.F., Li, G. & H\u00f6lscher, C. (2018) Two novel dual GLP-1\/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson\u2019s disease. Neuropharmacology, 133, 385\u2013394.","DOI":"10.1016\/j.neuropharm.2018.02.012"},{"key":"10.1016\/j.bcp.2026.118534_b0105","doi-asserted-by":"crossref","first-page":"157","DOI":"10.3233\/JPD-181503","article-title":"Semaglutide is Neuroprotective and Reduces alpha-Synuclein Levels in the Chronic MPTP Mouse Model of Parkinson's Disease","volume":"9","author":"Zhang","year":"2019","journal-title":"J. Parkinsons Dis."},{"key":"10.1016\/j.bcp.2026.118534_b0110","doi-asserted-by":"crossref","first-page":"e2231","DOI":"10.1002\/brb3.2231","article-title":"The GLP-1\/GIP dual-receptor agonist DA5-CH inhibits the NF-kappaB inflammatory pathway in the MPTP mouse model of Parkinson's disease more effectively than the GLP-1 single-receptor agonist NLY01","volume":"11","author":"Lv","year":"2021","journal-title":"Brain Behav."},{"key":"10.1016\/j.bcp.2026.118534_b0115","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2025.177972","article-title":"The novel GLP-1 \/ GIP dual agonist DA3-CH is more effective than liraglutide in the MPTP mouse model of Parkinson's disease","volume":"1003","author":"Feng","year":"2025","journal-title":"Eur. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.bcp.2026.118534_b0120","article-title":"Recent advances and Therapeutic Benefits of Glucagon-like Peptide-1 (GLP-1) Agonists in the Management of Type 2 Diabetes and Associated Metabolic Disorders","volume":"16","author":"Olukorode","year":"2024","journal-title":"Cureus"},{"issue":"7","key":"10.1016\/j.bcp.2026.118534_b0125","doi-asserted-by":"crossref","first-page":"3812","DOI":"10.3390\/ijms25073812","article-title":"GLP-1 Receptor Agonists: a New Treatment in Parkinson's Disease","volume":"25","author":"Kalinderi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.bcp.2026.118534_b0130","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41380-022-01792-4","article-title":"Incretin and insulin signaling as novel therapeutic targets for Alzheimer's and Parkinson's disease","volume":"28","author":"Nowell","year":"2023","journal-title":"Mol. Psychiatry"},{"issue":"14","key":"10.1016\/j.bcp.2026.118534_b0135","article-title":"Beneficial effects of Apelin-13 on metabolic diseases and exercise","volume":"28","author":"Wen","year":"2023","journal-title":"Front Endocrinol (lausanne)."},{"key":"10.1016\/j.bcp.2026.118534_b0140","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.90773","article-title":"Dynamic allosteric networks drive adenosine A1 receptor activation and G-protein coupling","volume":"12","author":"Maria-Solano","year":"2023","journal-title":"Elife"},{"issue":"6","key":"10.1016\/j.bcp.2026.118534_b0145","doi-asserted-by":"crossref","first-page":"2092","DOI":"10.1093\/brain\/awac087","article-title":"Striatal synaptic bioenergetic and autophagic decline in premotor experimental parkinsonism","volume":"145","author":"Merino-Gal\u00e1n","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.bcp.2026.118534_b0150","article-title":"Early \u03b1-synuclein\/synapsin III co-accumulation, nigrostriatal dopaminergic synaptopathy and denervation in the MPTPp mouse model of Parkinson's Disease","volume":"383","author":"Serra","year":"2024","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.bcp.2026.118534_b0155","first-page":"1","article-title":"Mitochondrial dysfunction in Parkinson's disease: Insights from ultrastructural and biochemical analyses","volume":"208","author":"Shrestha","year":"2023","journal-title":"Free Radic. Biol. Med."},{"issue":"16","key":"10.1016\/j.bcp.2026.118534_b0160","doi-asserted-by":"crossref","first-page":"5933","DOI":"10.3390\/ijms21165933","article-title":"How do Molecular Dynamics Data Complement Static Structural Data of GPCRs","volume":"21","author":"Torrens-Fontanals","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118534_b0165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1146\/annurev.ne.11.030188.000501","article-title":"MPTP toxicity: implications for research in Parkinson's disease","volume":"11","author":"Kopin","year":"1988","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.bcp.2026.118534_b0170","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0922-4106(91)90073-Q","article-title":"MPTP mechanisms of neurotoxicity and their implications for Parkinson's disease","volume":"208","author":"Gerlach","year":"1991","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118534_b0175","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1038\/nrendo.2009.48","article-title":"Incretin-based therapies for type 2 diabetes mellitus","volume":"5","author":"Lovshin","year":"2009","journal-title":"Nat. Rev. Endocrinol."},{"key":"10.1016\/j.bcp.2026.118534_b0180","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1)","volume":"30","author":"M\u00fcller","year":"2019","journal-title":"Mol. Metab."},{"key":"10.1016\/j.bcp.2026.118534_b0185","doi-asserted-by":"crossref","DOI":"10.3389\/fnins.2022.970925","article-title":"The neuroprotective effects of glucagon-like peptide 1 in Alzheimer's and Parkinson's disease: an in-depth review","volume":"16","author":"Reich","year":"2022","journal-title":"Front. Neurosci."},{"key":"10.1016\/j.bcp.2026.118534_b0190","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/S0140-6736(24)02808-3","article-title":"Exenatide once a week versus placebo as a potential disease-modifying treatment for people with Parkinson's disease in the UK: a phase 3, multicentre, double-blind, parallel-group, randomised, placebo-controlled trial","volume":"405","author":"Vijiaratnam","year":"2025","journal-title":"Lancet"},{"key":"10.1016\/j.bcp.2026.118534_b0195","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1474-4422(23)00378-2","article-title":"Safety, tolerability, and efficacy of NLY01 in early untreated Parkinson's disease: a randomised, double-blind, placebo-controlled trial","volume":"23","author":"McGarry","year":"2024","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.bcp.2026.118534_b0200","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int J Obes"},{"key":"10.1016\/j.bcp.2026.118534_b0205","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114187","article-title":"Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics","volume":"180","author":"Salameh","year":"2020","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118534_b0210","first-page":"34222","article-title":"Elabela\/Toddler peptide protects the embryonic heart from apoptosis in an APJ-dependent manner","volume":"6","author":"Murza","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118534_b0215","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ejphar.2017.06.029","article-title":"A novel GLP-1\/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease","volume":"812","author":"Yuan","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118534_b0220","doi-asserted-by":"crossref","first-page":"523","DOI":"10.3233\/JPD-191768","article-title":"The novel dual GLP-1\/GIP receptor agonist DA-CH5 is superior to single GLP-1 receptor agonists in the MPTP model of Parkinson\u2019s disease","volume":"10","author":"Zhang","year":"2020","journal-title":"J Parkinson Dis"},{"key":"10.1016\/j.bcp.2026.118534_b0225","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/1428817","article-title":"DA5-CH and Semaglutide Protect against Neurodegeneration and Reduce alpha-Synuclein Levels in the 6-OHDA Parkinson's Disease Rat Model","volume":"2022","author":"Zhang","year":"2022","journal-title":"Parkinson's Disease"},{"key":"10.1016\/j.bcp.2026.118534_b0230","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/7427136","article-title":"A dual GLP-1\/GIP Receptor Agonist is more Effective than Liraglutide in the A53T Mouse Model of Parkinson's Disease","volume":"2023","author":"Zhang","year":"2023","journal-title":"Parkinson's Disease"},{"key":"10.1016\/j.bcp.2026.118534_b0235","doi-asserted-by":"crossref","first-page":"2131","DOI":"10.1053\/j.gastro.2007.03.054","article-title":"Biology of incretins: GLP-1 and GIP","volume":"132","author":"Baggio","year":"2007","journal-title":"Gastroenterology"},{"key":"10.1016\/j.bcp.2026.118534_b0240","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.neuropharm.2015.10.002","article-title":"Neuroprotective effects of a GIP analogue in the MPTP Parkinson's disease mouse model","volume":"101","author":"Li","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.bcp.2026.118534_b0245","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ejphar.2016.11.050","article-title":"D-Ala2-GIP-glu-PAL is neuroprotective in a chronic Parkinson's disease mouse model and increases BNDF expression while reducing neuroinflammation and lipid peroxidation","volume":"797","author":"Li","year":"2017","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.bcp.2026.118534_b0250","doi-asserted-by":"crossref","DOI":"10.1016\/j.peptides.2019.170184","article-title":"GIP has neuroprotective effects in Alzheimer and Parkinson's disease models","volume":"125","author":"Zhang","year":"2020","journal-title":"Peptides"},{"issue":"14","key":"10.1016\/j.bcp.2026.118534_b0255","doi-asserted-by":"crossref","first-page":"7809","DOI":"10.3390\/ijms23147809","article-title":"In Silico Study of Allosteric Communication Networks in GPCR Signaling Bias","volume":"23","author":"Morales-Pastor","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2026.118534_b0260","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1159\/000433437","article-title":"Molecular Pharmacology of the Incretin Receptors","volume":"25 Suppl 1(Suppl 1)","author":"Al-Sabah","year":"2016","journal-title":"Med. Princ. Pract."},{"issue":"7","key":"10.1016\/j.bcp.2026.118534_b0265","doi-asserted-by":"crossref","first-page":"40335","DOI":"10.1038\/srep40335","article-title":"Apelin receptor homodimer-oligomers revealed by single-molecule imaging and novel G protein-dependent signaling","volume":"16","author":"Cai","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118534_b0270","doi-asserted-by":"crossref","DOI":"10.1016\/j.redox.2020.101629","article-title":"Individual phosphorylation sites at the C-terminus of the apelin receptor play different roles in signal transduction","volume":"36","author":"Chen","year":"2020","journal-title":"Redox Biol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118534_b0275","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.ijo.0802206","article-title":"Entry of exendin-4 into brain is rapid but may be limited at high doses","volume":"27","author":"Kastin","year":"2003","journal-title":"Int. J. Obes. Relat. Metab. Disord."},{"key":"10.1016\/j.bcp.2026.118534_b0280","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s40120-025-00724-y","article-title":"Are Glucagon-like Peptide-1 (GLP-1) Receptor Agonists Central nervous System (CNS) Penetrant: a Narrative Review","volume":"14","author":"West","year":"2025","journal-title":"Neurol. Ther."},{"issue":"8\u20139","key":"10.1016\/j.bcp.2026.118534_b0285","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1051\/medsci\/2005218-9741","article-title":"Apelin, a neuropeptide that counteracts vasopressin secretion","volume":"21","author":"Llorens-Cort\u00e8s","year":"2005","journal-title":"Med. Sci. (Paris)"},{"issue":"2","key":"10.1016\/j.bcp.2026.118534_b0290","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s11033-022-08075-9","article-title":"Apelin\/APJ system: an emerging therapeutic target for neurological diseases","volume":"50","author":"Li","year":"2023","journal-title":"Mol. Biol. Rep."},{"issue":"1","key":"10.1016\/j.bcp.2026.118534_b0295","first-page":"1","article-title":"Gender differences on MPTP neurotoxicity in C57BL\/6 mice","volume":"314","author":"Ookubo","year":"2009","journal-title":"Mol. Cell. Endocrinol."},{"issue":"23","key":"10.1016\/j.bcp.2026.118534_b0300","doi-asserted-by":"crossref","first-page":"8247","DOI":"10.1523\/JNEUROSCI.23-23-08247.2003","article-title":"Chromosomal loci influencing susceptibility to the parkinsonian neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine","volume":"23","author":"Sedelis","year":"2003","journal-title":"J. Neurosci."},{"issue":"4","key":"10.1016\/j.bcp.2026.118534_b0305","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.pbb.2010.03.009","article-title":"Sex differences in motor behavior in the MPTP mouse model of Parkinson's disease","volume":"95","author":"Antzoulatos","year":"2010","journal-title":"Pharmacol. Biochem. Behav"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008762?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008762?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T23:19:16Z","timestamp":1791933556000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008762"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":61,"alternative-id":["S0006295226008762"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118534","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A GLP-1\/apelin dual receptor agonist shows neuroprotective effects in the MPTP mouse model of Parkinson\u2019s disease","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118534","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118534"}}